Study S001500

A Phase 3, Randomized, Multicenter, Double-Blind Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)

ClinicalTrials.gov record

Registration

Registration: NCT06354660
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: COMPLETED
Enrollment: 537
Start: 2024-04-10
Primary completion: 2026-01-22
Lead sponsor: Eli Lilly and Company
Conditions: Diabetes Type 2
Interventions: DRUG:Retatrutide; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:J1I-MC-GZBY

Registered primary outcomes

Change from Baseline in Hemoglobin A1c (HbA1c) (%) [Baseline, Week 40]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0009259	Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Bajaj HS, Lancet (London, England)	2026	Randomized trial	PMID 42250575 DOI	cites ClinicalTrials.gov:NCT06354660; registry reference DERIVED:42250575